617. Acute Myeloid Leukemias: Commercially Available Therapies: Poster I

A phase II study of IDH1 inhibition with ivosidenib as maintenance therapy after ivosidenib azacitidine and venetoclax for Acute Myeloid Leukemia Trial in progress

Intermediate‑dose cytarabine is noninferior to high‑dose cytarabine for AML consolidation A systematic review and meta‑analysis

Selinexor in combination with venetoclax and azacitidine for newly diagnosed ND unfit Acute Myeloid Leukemia AML A multicenter open label prospective study

The addition of venetoclax to FLAG IDA or FCE in relapsed or refractory R R acute myeloid leukemia AML

Impact of midostaurin in younger AML patients intensively treated with high dose anthracycline

Extended aprepitant in control of delayed emesis during induction chemotherapy for acute myeloid leukaemia – an multicentric investigator initiated open label randomized controlled trial

Safety and efficacy of venetoclax plus CAG cytarabine aclarubicin G CSF regimen in patients with relapsed or refractory Acute Myeloid Leukemia A prospective single arm phase II study

Hypomethylating agents or chemotherapy in combination with venetoclax and gilteritinib for FLT3 mutated Acute Myeloid Leukemia

Cladribine idarubicin and AraC CLIA combined with a FLT3 inhibitor in patients with newly diagnosed FLT3 mutated Acute Myeloid Leukemia A pooled analysis of prospective trials

Concurrent use of nucleoside reverse transcriptase inhibitors and purine analogs is associated with worse survival for patients with myeloid neoplasms A single center retrospective analysis

10 day decitabine versus conventional chemotherapy 3 7 followed by allografting in AML patients ≥ 60 years Long term follow up results of the randomized phase III trial AML21 of the EORTC leukemia group GIMEMA and german MDS Study group

Venetoclax combined with three day multi frequency Decitabine  DEC3 VEN in the treatment of adult patients with de novo Acute Myeloid Leukemia updated results of a phase II trial

Efficacy of a venetoclax based anthracycline free regimen in newly diagnosed CBFβ MYH11 acute myeloid leukemia

Selinexor based non intensive chemotherapy regimens adjusted according to early responses achieve high early remission in newly diagnosed AML or MDS

FLT3 inhibition with midostaurin offsets poor prognosis in NPM1 FLT3 DNMT3a triple mutated AML

Oral etoposide vs intravenous daunorubicin plus ATRA RIF as induction therapy for low risk acute promyelocytic leukemia A phase II randomized controlled Trial

Efficacy and safety of sorafenib combined with Standard  Chemotherapy in adult patients with Myeloid sarcoma A multi center cohort study

Real world outcomes of shortened venetoclax course plus decitabine in newly diagnosed acute myeloid leukemia

Real world analysis of time spent at home for patients with secondary acute myeloid leukemia treated with CPX 351 or venetoclax plus azacitidine in England

High remission rates with FLAG ida venetoclax in acute myeloid leukemia Less is More on days of venetoclax in the intensive regimen

Efficacy and safety of azacitidine venetoclax combined with gha priming regimen in the treatment of adult refractory and relapsed acute myeloid leukemia A prospective single arm multicenter study

Transfusion burden among older US patients with relapsed FLT3 mutated Acute Myeloid Leukemia treated with gilteritinib A Medicare claims based cohort study

A randomized phase 2 trial of CPX 351 vs CLAG m Cladribine High Dose Cytarabine G CSF and Mitoxantrone in medically less fit adults with previously untreated acute myeloid leukemia AML or other high grade myeloid neoplasms

Low dose chemotherapy for induction in pediatric AML Retrospective outcome analysis across expanded cohorts

Real world survival outcomes with first line venetoclax therapy in AML

Clinical characteristics and response in olutasidenib treated Relapsed Refractory mIDH1 Acute Myeloid Leukemia AML patients with stable disease following two treatment cycles

Real life study of ivosidenib in either monotherapy or combined with azacytidine for first line mutant IDH1 AML A study from the french AML intergroup ALFA filo